ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

ARGX argenx SE

360.23
1.82 (0.51%)
20 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
argenx SE ARGX 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
1.82 0.51% 360.23 09:00:00
개장가 저가 고가 종가 전일 종가
360.38 357.55 362.535 360.23 358.41
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
16/04/202414:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202415:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
27/03/202405:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202415:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08/03/202420:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/03/202406:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
01/03/202406:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/02/202415:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202415:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202415:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/02/202415:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202420:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/01/202415:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202415:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202415:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
21/12/202302:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202320:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202315:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
29/11/202301:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202321:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202320:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202315:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
17/11/202320:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/11/202321:40GLOBEargenx Announces European Commission Approval of..
02/11/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202315:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202322:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202314:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
28/09/202305:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
21/09/202321:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/09/202314:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/09/202314:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/08/202314:00GLOBEargenx to Present at Upcoming Investor Conferences
27/07/202319:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/07/202314:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
25/07/202305:30GLOBEargenx announces closing of global offering
21/07/202305:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/07/202314:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
20/07/202306:58GLOBEargenx announces full exercise of underwriters’ option to..
19/07/202310:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
18/07/202305:58DJNArgenx Launches $750 Million Global Offering
18/07/202305:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/07/202305:01GLOBEargenx announces launch of proposed global offering
18/07/202300:59DJNArgenx Up Over 30%, on Track for Record High Close -- Data..
18/07/202300:04DJNArgenx Shares Hit 52-Week High After Positive Vyvgart..
17/07/202320:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/07/202320:10DJNArgenx, Zai Lab Shares Rise After Positive Trial Results for..

최근 히스토리

Delayed Upgrade Clock